Q BioMed Inc (QBIO)

[StockHighAlert-]

Enter Big Pharma

As accuracy of the GDF15 biomarker is further affirmed, it could ultimately be used as a surrogate biomarker to ocular therapy clinical trial endpoints—perhaps even used as a primary endpoint in MAN-01 trials and studies. In this scenario, major pharmaceuticals engaging in glaucoma or tangentially-related glaucoma or ocular clinical trials may elect to license the biomarker so that they may have access to it for the trials.

By leveraging a single platform, QBIO has multiple shots on goal with respect to market share, revenue and profit in the multi-billion dollar glaucoma market. A unique player on the path to offering a series of "firsts", QBIO is leading innovation in the lucrative ophthalmology segment, which carries high price/revenue multiples.